Drug Profile
AL 034
Alternative Names: AL-034; JNJ-4964; JNJ-64794964; TQ-A3334Latest Information Update: 12 Dec 2023
Price :
$50
*
At a glance
- Originator Chia Tai Tianqing Pharmaceutical Group
- Developer Alios BioPharma; Chia Tai Tianqing Pharmaceutical Group
- Class Antineoplastics; Antivirals; Immunotherapies
- Mechanism of Action Toll-like receptor 7 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hepatitis B
- Phase I/II Non-small cell lung cancer
Most Recent Events
- 07 Dec 2023 Chia Tai Tianqing Pharmaceutical Group plans a phase I trial for Hepatitis B (In volunteers) (PO, Tablet) in January 2024 (NCT06160895)
- 10 Nov 2023 Efficacy and adverse event data from the phase II OCEAN cure05 trial presented at the Liver Meeting 2023 74th Annual Meeting of the American Association for the Study of Liver (AASLD-2023)
- 28 Nov 2020 No recent reports of development identified for phase-I development in Hepatitis-B(In volunteers, In adults) in China (PO)